ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1306

High Prevalence of Previously Undiagnosed Axial Spondyloarthritis in Patients Referred with Anterior Uveitis and Chronic Back Pain

Rianne van Bentum1, Frank Verbraak2, Sanne Wolf3, Maarten Boers4, Stevie Tan5 and Irene van der Horst-Bruinsma1, 1Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, 2Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, 3Amsterdam University Medical Center location VUmc, Amsterdam, Netherlands, 4Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, 5Amsterdam University Medical Center, Amsterdam, Netherlands

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), Back pain, Spondylarthropathies, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To reduce the diagnostic delay in axial spondyloarthritis (axSpA), Rheumatology and Ophthalmology guidelines recommend to refer patients with acute anterior uveitis (AAU) and chronic back pain (CBP) to a rheumatologist. The impact of these recommendations in daily practice, has not yet been described. This study evaluated the prevalence of previously unrecognized axSpA in AAU patients with CBP, referred by ophthalmologists following a short instructional course to increase awareness. Secondary aims were to evaluate the timing of onset of AAU and CBP, and gender differences.

Methods: This cross sectional study included AAU patients referred with CBP (≥3 months, started < 45 years of age), from five Ophthalmology clinics. Patients with a previously diagnosed rheumatic disease, or an established other cause of AAU, were excluded. All patients underwent thorough rheumatologic evaluation, including assessment of ASAS inflammatory back pain (IBP), ASAS SpA features, laboratory examination and pelvis radiography (evaluated based on the modified New York (mNY) criteria for sacroiliitis). The primary endpoint was a clinical axSpA diagnosis (definite/possible/no axSpA), made by the rheumatologist. Patients with a definite- or possible diagnosis were classified according to the ASAS classification criteria for axSpA.

Results: Of the 101 referrals, 81 patients fulfilled the referral criteria (52% male, median age 41 years, median back pain onset 10 years before referral, Table 1). IBP was present in 53%, 56% was HLA-B27 positive, and 32% had some level of radiographic sacroiliac joint abnormalities (of whom 42% fulfilled the mNY criteria). Eventually, 23% (n=19) was clinically diagnosed with definite-axSpA (100% fulfilling the ASAS axSpA criteria; 53% radiographic) and 41% (n=33) with possible-axSpA (55% fulfilling the ASAS axSpA criteria; 6% radiographic). Importantly, of the 47 patients with recurring AAU, 87% had already had CBP during previous AAUs. Men had the same chance of fulfilling the ASAS axSpA criteria as women (57%, vs 56%), and did not differ in number of SpA features, HLA-B27, back pain duration and IBP. However, men were more likely to be clinically diagnosed with axSpA (33% versus 13% in women). 

Conclusion: The referral of AAU patients with CBP resulted in 23% new axSpA diagnoses (more prevalent in men), and another 41% required follow up because of a suspicion of early axSpA. There was a substantial diagnostic delay in the majority of patients with recurring AAU, as many already had back pain during previous AAU. In AAU, screening for CBP and prompt referral has a high diagnostic yield, and should consistently be promoted among ophthalmologists and rheumatologists.

Table 1. Patient characteristics at referral, subdivided for the clinical diagnoses.


Disclosure: R. van Bentum, None; F. Verbraak, Bayer, 2, 5, 8, Novartis, 2, 5, 8, IDxDR, 2, 5, 8, UCB Pharma, 2, 5, 8; S. Wolf, None; M. Boers, None; S. Tan, None; I. van der Horst-Bruinsma, AbbVie, 1, 2, 3, UCB Pharma, 2, 5, 8, Merck Sharp & Dohme, 1, 2, 3, Novartis, 1, Pfizer, 1, 2, Bristol-Myers Squibb, 1.

To cite this abstract in AMA style:

van Bentum R, Verbraak F, Wolf S, Boers M, Tan S, van der Horst-Bruinsma I. High Prevalence of Previously Undiagnosed Axial Spondyloarthritis in Patients Referred with Anterior Uveitis and Chronic Back Pain [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/high-prevalence-of-previously-undiagnosed-axial-spondyloarthritis-in-patients-referred-with-anterior-uveitis-and-chronic-back-pain/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-prevalence-of-previously-undiagnosed-axial-spondyloarthritis-in-patients-referred-with-anterior-uveitis-and-chronic-back-pain/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology